Login / Signup

Treatment-free remission after third-line therapy with asciminib in chronic myeloid leukemia with an atypical e19a2 BCR::ABL1 transcript and T315I mutation.

Philipp ErnstJenny RinkeGeorg-Nikolaus FrankeFrank DickerTorsten HaferlachThomas ErnstAndreas Hochhaus
Published in: Leukemia (2024)
Keyphrases
  • chronic myeloid leukemia
  • tyrosine kinase
  • rna seq
  • disease activity
  • rheumatoid arthritis
  • combination therapy
  • replacement therapy